Detection of bioprosthetic valve degeneration
The invention relates to a method for predicting or diagnosing a risk of bioprosthetic valve degeneration. Further, the invention relates to a medical device, in particular a bioprosthetic valve coated with EPCR less prone to degeneration and/or calcification once implanted.
1. A method for diagnosing or monitoring a risk of bioprosthetic valve degeneration, said method comprising the following steps:
i) selecting a subject that has undergone bioprosthetic surgical valve replacement;
ii) measuring sEPCR level or amount in a biological sample previously collected from said subject, and
iii) comparing said level or amount to a reference, wherein diagnosis or monitoring is based on the result of the comparing step.
2. The method for diagnosing or monitoring according to claim 1 , wherein measuring sEPCR level or amount according to step ii) comprises contacting said sample with a sEPCR binding partner.
3. A method for diagnosing or monitoring a risk of bioprosthetic valve degeneration in a subject, said method comprising the following steps:
i) measuring sEPCR level or amount in a biological sample previously collected from said subject, and
ii) comparing said level or amount to a reference, wherein diagnosis or monitoring is based on the result of the comparing step, and
wherein said method further comprises a pretreatment step of said sample before step i).
4. The method for diagnosing or monitoring according to claim 3 wherein said pretreatment step comprises a transformation of sEPCR for measuring the level or amount of sEPCR.
5. The method for diagnosing or monitoring according to claim 4 wherein the step ii) comprises contacting the transformed sEPCR with a binding partner capable of selectively interacting with said transformed sEPCR.
6. A method for diagnosing or monitoring a risk of bioprosthetic valve degeneration in a subject, said method comprising the following steps,
i) measuring sEPCR level or amount in a biological sample previously collected from said subject, and
ii) comparing said level or amount to a reference, wherein diagnosis or monitoring is based on the result of the comparing step, and
wherein when the level of sEPCR is lower than 130 ng/mL, then the subject is diagnosed as suffering or at risk of suffering from bioprosthetic valve degeneration.
7. A method for diagnosing or monitoring a risk of bioprosthetic valve degeneration in a subject, said method comprising the following steps,
i) measuring sEPCR level or amount in a biological sample previously collected from said subject, and
ii) comparing said level or amount to a reference wherein diagnosis or monitoring is based on the result of the comparing step, and
wherein the level of sEPCR is lower than 108 ng/mL, then the subject is diagnosed as suffering or at risk of suffering from bioprosthetic valve degeneration.
8. The method for diagnosing or monitoring according to claim 1 , wherein the sample is selected from whole blood, serum or plasma.
9. The method for diagnosing or monitoring according to claim 1 further comprising a step iv) consisting in implementing appropriate health care measures for said subject when the sEPCR level or amount is lower than the reference level or amount defined in step iii).
10. The method of diagnosing or monitoring according to claim 9 , wherein the implemented healthcare measure is selected from administering to said subject at least one anticoagulant medication, at least one preventive treatment or measure of heart failure or atrial fibrillation, or performing on said subject an echocardiography, or a combination thereof.
11. A bioprosthetic tissue to be implanted in the body of a subject coated with EPCR protein, sEPCR, extracellular part of EPCR, or a fragment thereof.
12. The bioprosthetic tissue according to claim 11 , wherein said bioprosthetic tissue comprises a chemically grafted sEPCR, a chemically grafted extracellular part of EPCR or a chemically grafted fragment thereof tissue.
13. The bioprosthetic tissue according to claim 11 , wherein the tissue is colonized with cells expressing EPCR.
14. The bioprosthetic tissue according to claim 11 , wherein the tissue is made of bovine, calf, equine, or porcine pericardium, or of porcine aortic valve.
15. A bioprosthetic valve to be implanted in a subject comprising a tissue according to claim 14 .
16. A device adapted for carrying out the method of diagnosing or monitoring according to any of claims 1 to 8 comprising:
an analyzing unit adapted for measuring the amount or level of sEPCR in a sample of a subject; and
an evaluation unit comprising a stored reference and a data processor having implemented an algorithm for comparing the amount of sEPCR measured by the analyzing unit with at least one stored reference.
17. A method of treating slowing or stopping bioprosthetic valve degeneration and/or calcification in a subject suffering or at risk of suffering from valve degeneration and/or calcification, comprising administering to the subject at least one anticoagulant medication, selected from:
a vitamin K antagonist,
an heparinoid,
an antiplatelets agents,
a thrombin inhibitor,
an inhibitor of factor Xa,
other antiplatelet agents, or
a combination thereof.
18. A method of treating valvopathy comprising using a bioprosthetic valve according to claim 15 .
19. The method of claim 6 , wherein when the level of sEPCR is lower than 110 ng/mL, then the subject is diagnosed as suffering or at risk of suffering from bioprosthetic valve degeneration.
20. The method of claim 17 , wherein the anticoagulant medication is acetylsalicylic acid.